
|Articles|October 15, 2002
Head-to-head trial: Phase III study tests options for wet AMD
Fort Worth, TX-Alcon Research Ltd. is enrolling about 500 patients in a phase III study to compare the effects of anecortave acetate versus verteporfin (Visudyne, Novartis) photodynamic therapy for the treatment of wet age-related macular degeneration.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaucoma 2026: Which emerging technologies will change practice?
2
How AI is reshaping ophthalmology in 2025 and beyond
3
Molecular insights and clinical experience: Extending anti-VEGF durability
4
Reimagining dry eye care: Focus on sustained tear production
5












































